At a Glance
- Drugs that decreased the number of non-functional (senescent) cells in the body helped mice live longer and maintain their physical abilities.
- Clinical trials are needed to test whether this approach can safely and effectively extend health span in people.
Dasatinib, one of the two drugs in the senolytic cocktail used in the study, is an anti-cancer drug. The other drug in the cocktail, quercetin, is an antioxidant found in some foods. serge001/iStock/Thinkstock
As the body ages, physical abilities decline. This can lead to difficulty with daily tasks and eventually loss of the ability to live independently. Senescent cells are thought to play a role in this aspect of the aging process. Cells that are senescent no longer do their jobs or divide, but are still alive. In addition, they release molecules that can harm healthy cells around them and may even induce other cells to become senescent.
A team of researchers led by Dr. James Kirkland of the Mayo Clinic wanted to understand how senescent cells contribute to the physical effects of aging. Their study was supported by NIH’s National Institute on Aging (NIA) and others. The findings were published on July 9, 2018, in Nature Medicine.
The scientists first transplanted a small number of senescent fat cells into healthy young and middle-aged mice, and measured how those cells impacted strength, endurance, and other measures of physical health. For comparison, control mice were given fat cells that weren’t senescent.
One month after transplantation, mice who received the senescent cells had impaired walking speed, physical endurance, and grip strength compared to control mice. Larger doses of senescent cells caused greater impairment over time. Notably, middle-aged mice transplanted with senescent cells had a 5-fold higher risk of death than control mice over the following year.
The negative physical effects observed didn’t appear to be due to rejection of the transplanted cells by the body. The effects of the senescent cells also lasted longer in the body than the cells themselves. Results suggested that the senescent cells may have caused previously healthy cells to become senescent.
The team next tested whether drugs that are known to eliminate senescent cells, called senolytics, could slow or reverse these effects. A cocktail of two senolytic drugs, dasatinib and quercetin, was given to young mice either at the same time as transplantation of senescent cells or 5 weeks afterward. In both cases, the drug combination improved physical functioning. The effects of a single treatment lasted several months.
When the researchers gave the cocktail over 4 months to mice who had aged naturally to the human equivalent of 75 to 90 years of age, they saw similar improvements in physical abilities compared with untreated mice. Mice who received the drugs also lived 36% longer on average and were no more frail near their delayed time of death than controls.
“We can say with certainty that senescent cells can cause health problems in young mice, including causing physical dysfunction and lowering survival rates, and that the use of senolytics can significantly improve both health span and life span in much older naturally aged animals,” Kirkland says.
The authors caution that clinical trials are needed to test the safety and effectiveness of this approach in people.
- Drugs Extend Healthy Lifespan in Mice
- Senescent Cells Tied to Health and Longevity in Mice
- Physical Activity May Reduce Age-Related Movement Problems
- Physical Activity Program Helps Maintain Mobility
- You’re Never Too Old
References: Senolytics improve physical function and increase lifespan in old age. Xu M, Pirtskhalava T, Farr JN, Weigand BM, Palmer AK, Weivoda MM, Inman CL, Ogrodnik MB, Hachfeld CM, Fraser DG, Onken JL, Johnson KO, Verzosa GC, Langhi LGP, Weigl M, Giorgadze N, LeBrasseur NK, Miller JD, Jurk D, Singh RJ, Allison DB, Ejima K, Hubbard GB, Ikeno Y, Cubro H, Garovic VD, Hou X, Weroha SJ, Robbins PD, Niedernhofer LJ, Khosla S, Tchkonia T, Kirkland JL. Nat Med. 2018 Jul 9. doi: 10.1038/s41591-018-0092-9. [Epub ahead of print]. PMID: 29988130.
Funding: NIH’s National Institute on Aging (NIA), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Glenn Foundation; American Federation for Aging Research; Ted Nash Long Life Foundation; Noaber Foundation; and Irene Diamond Fund.
Search NIH Research Matters
Search NIH Research Matters' stories
In this Edition
Technique may improve detection of breast tumors
Protective liquid enables oral insulin delivery in rats
Eliminating senescent cells extends healthy life in mice
Connect with Us
Subscribe to get NIH Research Matters by email
- RSS Feed
- Facebook(link is external)
- Email us(link sends e-mail)
NIH Research Matters
Bldg. 31, Rm. 5B52, MSC 2094
Bethesda, MD 20892-2094
Epstein-Barr virus and autoimmune diseases
Breast cancer patient benefits from modified immunotherapy
Immune-suppressing drugs linked to lower risk of Parkinson’s disease
Intensive weight loss helps knee arthritis
Healthy diets linked to lower risk of hearing loss in women
About NIH Research Matters
Editor: Harrison Wein, Ph.D. Assistant Editors: Tianna Hicklin, Ph.D., Geriann Piazza
NIH Research Matters is a weekly update of NIH research highlights reviewed by NIH’s experts. It's published by the Office of Communications and Public Liaisonin the NIH Office of the Director.